Categories: News

FormFactor Announces Participation at the 23rd Annual Needham Growth Conference

LIVERMORE, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) — FormFactor, Inc. (Nasdaq:FORM) is pleased to announce its participation in the following investor conference:

Needham 23rd Annual Growth Conference
Location: Virtual
Date: January 13th, 2021
Presentation Time: 2:45 pm ET

The public is invited to listen to a live webcast of FormFactor’s presentation, which can be accessed from the investors’ section of the company’s website at www.formfactor.com. Replay of the webcast will also be available at www.formfactor.com.

About FormFactor:

FormFactor, Inc. (NASDAQ:FORM), is a leading provider of essential test and measurement technologies along the full IC life cycle – from metrology and inspection, characterization, modeling, reliability, and design de-bug, to qualification and production test. Semiconductor companies rely upon FormFactor’s products and services to accelerate profitability by optimizing device performance and advancing yield knowledge. The Company serves customers through its network of facilities in Asia, Europe, and North America. For more information, visit the Company’s website at www.formfactor.com.

Source: FormFactor, Inc.

FORM-F

Investor Contact:
Stan Finkelstein
Investor Relations
(925) 290-4321
ir@formfactor.com

Staff

Recent Posts

Bemax Announces Financial Results for Fiscal Fourth Quarter Ended May 31, 2024

- Revenue increase of over 600%Dallas, Georgia--(Newsfile Corp. - July 2, 2024) - Bemax Inc.…

3 hours ago

1933 Industries Reports Profit in Q3 2024 Financials

VANCOUVER, BC / ACCESSWIRE / July 2, 2024 / 1933 Industries Inc. (the "Company" or…

3 hours ago

Myriad Genetics Earns 2024 Great Place To Work® Certification™

SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a…

3 hours ago

Scilex Holding Company to Ring Nasdaq Closing Bell on Friday, July 5th at 4:00PM ET at the Nasdaq MarketSite in Times Square, New York

The ceremony will be held in celebration of Scilex’s launch of GLOPERBA®, an innovative non-opioid…

3 hours ago

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG…

3 hours ago